Midostaurin in Advanced Systemic Mastocytosis

Marie-Olivia Chandesris,Gandhi Damaj,Danielle Canioni,Chantal Brouzes,Ludovic Lhermitte,Katia Hanssens,Laurent Frenzel, Zoubair Cherquaoui, Isabelle Durieu,Stéphane Durupt, Emmanuel Gyan, Odille Beyne-Rauzy, David Launay, Cyril Faure,Mohamed Hamidou,Sophie Besnard,Momar Diouf, Aurélie Schiffmann, Mathilde Niault, Pierre-Yves Jeandel,Dana Ranta, Remi Gressin,Sylvain Chantepie,Stéphane Barete,Patrice Dubreuil,Philippe Bourget,Olivier Lortholary,Olivier Hermine

New England Journal of Medicine（2016）

引用 0|浏览7

暂无评分

摘要

The use of midostaurin, a multikinase inhibitor, has been associated with a response in 60% of patients with systemic mastocytosis, including mast-cell leukemia; the median overall survival was 28 months. A second, smaller trial in France showed a 71% response rate.

查看译文

关键词

midostaurin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要